Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: Intravenous immunoglobulin (IVIg)versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg

Clinical and Experimental Immunology

Volumn 177, Issue 2, 2014, Pages 464-477

  Zhu, D ^a,b   Ravindranath, M H ^a   Terasaki, P I ^a   Miyazaki, T ^c   Pham, T ^a   Jucaud, V ^a  

^a TERASAKI FOUNDATION LABORATORY   (United States)

^b FUDAN UNIVERSITY   (China)

^c Japanese Red Cross Hokkaido Block Blood Center   (Japan)

Author keywords

Allo HLA IgG; B memory cells; HLA reactivity; Immunosuppression; Intravenous immunoglobulin (IVIg)

Indexed keywords

ALLOANTIBODY; BETA 2 MICROGLOBULIN; HLA ANTIBODY; HLA B ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; TFL 007; UNCLASSIFIED DRUG;

ALLELE; ALLOIMMUNIZATION; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; HAPLOTYPE; HEAVY CHAIN; HLA SYSTEM; HLA TYPING; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMORY CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ALLO-HLA IGG; B MEMORY CELLS; HLA-REACTIVITY; IMMUNOSUPPRESSION; INTRAVENOUS IMMUNOGLOBULIN (IVIG);

ADULT; ALLELES; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; B-LYMPHOCYTES; CELLS, CULTURED; CHILD; EPITOPES, B-LYMPHOCYTE; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HLA-DR BETA-CHAINS; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; MALE; MICE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHENOTYPE; YOUNG ADULT;

EID: 84903955275     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12307     Document Type: Article

References (51)

1. Fulcher DA, Basten A. B cell life span: a review. Immunol Cell Biol 1997; 75:446-455.
2. Manz RA, Löhning M, Cassese G, Thiel A, Radbruch A. Survival of plasma cells is independent of Ag. Int Immunol 1998; 10:1703-1711.
3. Ahmed R, Gray D. Immunological memory and protective immunity: understand their relation. Science 1996; 272:54-60.
4. Radbruch A, Muehlinghaus G, Luger EO etal. Competence and competition: the challenge of becoming a long-live plasma cell. Nat Rev Immunol 2006; 6:741-750.
5. Luger EO, Fokuhl V, Wegmann M etal. Induction of allergen-specific plasma cells by mucosal allergen challenge. J Allergy Clin Immunol 2009; 124:819-826.
6. Terasaki PI, Cai J. Human leukocyte Ag Abs and chronic rejection: from association to causation. Transplantation 2008; 86:377-383.
7. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005; 17:541-545.
8. Marfo K, Lu A, Ling M, Akalin R. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6:922-936.
9. Montgomery RA, Lonze BE, King KE etal. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318-326.
10. Mao Q, Terasaki PI, Cai J etal. Extremely high association between appearance of HLA Abs and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007; 7:864-871.
11. Glotz D, Antoine C, Julia P etal. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2002; 2:758-760.
12. Jordan SC, Vo A, Bunnapradist S etal. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76:631-636.
13. Vo AA, Lukovsky M, Toyoda M etal. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359:242-251.
14. Rocha PN, Butterly DW, Greenberg A etal. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75:1490-1495.
15. Jordan SC, Vo AA, Tyan D, Nast CC, Toyoda M. Current approaches to treatment of Ab-mediated rejection. Pediatr Transplant 2005; 9:408-415.
16. Buckley RH, Schiff RI. The use of intravenous immune globulin in immuno-deficiency diseases. N Engl J Med 1991; 325:110-117.
17. Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD. Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases. Clin Exp Immunol 1991; 86:192-198.
18. McIntyre JA, Higgins N, Britton R etal. Utilization of intravenous immunoglobulin to ameliorate all-Abs in a highly sensitized patient with a cardiac assist device awaiting heart transplantation. Fluorescence-activated cell sorter analysis. Transplantation 1996; 62:691-693.
19. Glotz D, Haymann JP, Sansonetti N etal. Suppression of HLA-specific alloAbs by high-dose intravenous immunoglobulins (IVIg). A potential tool for transplantation of immunized patients. Transplantation 1993; 56:335-337.
20. Tyan DB, Li VA, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994; 57:553-562.
21. Ravindranath MH, Terasaki PI, Pham T, Jucaud V, Kawakita S. Therapeutic preparations of IVIg contain naturally occurring anti-HLA-E Abs that react with HLA-Ia (HLA-A/-B/-Cw) alleles. Blood 2013; 121:2013-2028.
22. de Grandmont MJ, Racine C, Roy A, Lemieux R, Néron S. Intravenous immunoglobulins induce the in vitro differentiation of human B lymphocytes and the secretion of IgG. Blood 2003; 101:3065-3073.
23. Heidt S, Roelen DL, Eijsink C, Eikmans M, Claas FH, Mulder A. Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production. Clin Exp Immunol 2009; 158:99-105.
24. Sundblad A, Huetz F, Portnoi D, Coutinho A. Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice. J Autoimmun 1991; 4:325-339.
25. Sundblad A, Marcos MA, Malanchere E etal. Observations on the mode of action of normal immunoglobulin at high doses. Immunol Rev 1994; 139:125-158.
26. Kondo N, Ozawa T, Mushiake K etal. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 1991; 11:152-158.
27. Han M, Rogers JA, Lavingia B, Stastny P. Peripheral blood B cells producing donor-specific HLA Abs in vitro. Hum Immunol 2009; 70:29-34.
28. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunopathol 1994; 73:180-186.
29. Sbrana S, Ruocco L, Vanacore R, Azzarà A, Ambrogi F. In vitro effects of an immunoglobulin preparation for intravenous use (IVIG) on T-cells activation. Allerg Immunol (Paris) 1993; 25:35-37.
30. Bayry J, Fournier EM, Maddur MS etal. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: a mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011; 36:9-15.
31. Prasad NK, Papoff G, Zeuner A etal. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998; 161:3781-3790.
32. Ravindranath MH, Taniguichi M, Chen CW etal. HLA-E monoclonal Abs recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA Abs. Mol Immunol 2010; 47:1121-1131.
33. Ravindranath MH, Pham T, El-Awar N, Kaneku H, Terasaki PI. Anti-HLA-E mAntibody 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: web-tools validate the immunogenic epitopes of HLA-E recognized by the Abs. Mol Immunol 2011; 48:423-430.
34. Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI. Abs to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J Immunol 2010; 185:1935-1948.
35. Coupel S, Moreau A, Hamidou M, Horejsi V, Soulillou JP, Charreau B. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2007; 109:2806-2814.
36. Arosa FA, Santos SG, Powis SJ. Open conformers: the hidden face of MHC-I molecules. Trends Immunol 2007; 28:115-123.
37. Schiff RI. Intravenous gammaglobulin: pharmacology, clinical uses and mechanisms of action. Pediatr Allergy Immunol 1994; 5:63-87.
38. Barocci S, Fenoglio D, Leprini A, Nocera A. Anti-HLA Abs(Ab1) and anti-idiotypic Abs (Ab2) directed against Anti-HLA Ab1 in various preparations of polyspecific immunoglobulins for intravenous use. Boll Soc Ital Biol Sper 1990; 66:1193-1200.
39. Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001; 108 (Suppl.):S95-98.
40. Nair V, Sawinski D, Akalin E etal. Effect of high-dose intravenous immunoglobulin on anti-HLA Abs in sensitized kidney transplant candidates. Clin Transplant 2012; 26:E261-268.
41. Alachkar N, Lonze BE, Zachary AA etal. Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte Ag Abs in highly sensitized patients. Transplantation 2012; 94:165-171.
42. Marfo K, Ling M, Bao Y etal. Lack of effect in desensitization with intravenous immunoglobulin and rituximantibody in highly sensitized patients. Transplantation 2012; 94:345-351.
43. Fecteau JF, Neron S. CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J Immunol 2005; 171:4621-4629.
44. Ettinger R, Sims GP, Fairhurst AM etal. IL-21 induces differentiation of human naive and memory B cells into Ab-secreting plasma cells. J Immunol 2005; 175:7867-7879.
45. Jego G, Bataille R, Pellat-Deceunynck C. Interleukin-6 is a growth factor for non-malignant human plasmablasts. Blood 2001; 97:1817-1822.
46. Jourdan M, Caraux A, De Vos J etal. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood 2009; 114:5173-5181.
47. Avery DT, Deenick EK, Ma CS etal. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing antibody responses in humans. J Exp Med 2010; 207:155-171.
48. + memory T cells by releasing Agic exosomes. J Immunol 2009; 182:1548-1559.
49. Polyak MJ, Deans JP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal Abs is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002; 99:3256-3262.
50. + T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood 2011; 118:992-1001.
51. Roura-Mir C, Catálfamo M, Cheng TY etal. CD1a and CD1c activate intrathyroidal T cells during Graves' disease and Hashimoto's thyroiditis. J Immunol 2005; 174:3773-3780.